Movement disorders : official journal of the Movement Disorder Society · 2026
Altered Cerebrospinal Fluid Tryptophan-Kynurenine Pathway Metabolism in Multiple System Atrophy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nagao Ryunosuke, Kawabata Kazuya, Mizutani Yasuaki, Shima Sayuri, Ueda Akihiro, Ito Mizuki, Maeda Yasuhiro, Mouri Akihiro, Watanabe Hirohisa
Аннотация
BACKGROUND: Alterations in tryptophan-kynurenine (TRP-KYN) metabolism, which is associated with neuroinflammation, remain unclear in multiple system atrophy (MSA).
OBJECTIVE: The aim was to investigate cerebrospinal fluid (CSF) TRP metabolites in MSA and their associations with other biomarkers.
METHODS: A total of 51 patients with MSA and 56 controls were included. CSF TRP metabolites, such as KYN, quinolinic acid (QA), and kynurenic acid (KA), along with neurofilament light chain (NfL), glycoprotein nonmetastatic melanoma protein B (GPNMB), and soluble triggering receptor expressed on myeloid cells 2 (sTREM2), were analyzed.
RESULTS: Patients with MSA exhibited higher levels of QA, a neuroinflammatory marker, and lower levels of KA, a neuroprotective marker, yielding an elevated QA-to-KA ratio. Neither QA nor KA correlated with clinical scores. GPNMB, sTREM2, and NfL were increased; however, these markers were independent of KYN pathway metabolites.
CONCLUSIONS: MSA exhibited a significant imbalance in KYN metabolism, suggesting a shift toward inflammatory processes distinct from classic neuroinflammatory markers. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
OBJECTIVE: The aim was to investigate cerebrospinal fluid (CSF) TRP metabolites in MSA and their associations with other biomarkers.
METHODS: A total of 51 patients with MSA and 56 controls were included. CSF TRP metabolites, such as KYN, quinolinic acid (QA), and kynurenic acid (KA), along with neurofilament light chain (NfL), glycoprotein nonmetastatic melanoma protein B (GPNMB), and soluble triggering receptor expressed on myeloid cells 2 (sTREM2), were analyzed.
RESULTS: Patients with MSA exhibited higher levels of QA, a neuroinflammatory marker, and lower levels of KA, a neuroprotective marker, yielding an elevated QA-to-KA ratio. Neither QA nor KA correlated with clinical scores. GPNMB, sTREM2, and NfL were increased; however, these markers were independent of KYN pathway metabolites.
CONCLUSIONS: MSA exhibited a significant imbalance in KYN metabolism, suggesting a shift toward inflammatory processes distinct from classic neuroinflammatory markers. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.